Back to top
more

Patterson Companies (PDCO)

(Real Time Quote from BATS)

$21.45 USD

21.45
293,523

-0.48 (-2.19%)

Updated Sep 5, 2024 01:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (170 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Edwards Lifesciences (EW) Gets CE Mark for PASCAL Precision

by Zacks Equity Research

Edwards Lifesciences' (EW) PASCAL Precision system enables precise navigation and implant delivery during mitral and tricuspid regurgitation treatment.

Here's Why Investors Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic's (HOLX) better-than-expected results and expanded Panther installed base.

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.

IDEXX (IDXX) Suffers From Macro Headwinds, Cost Constraints

by Zacks Equity Research

The strengthening of the rate of exchange for the U.S. dollar relative to other currencies has a negative impact on IDEXX's (IDXX) revenues.

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

BD's (BDX) Latest Collaboration to Boost Patient Outcome

by Zacks Equity Research

BD's (BDX) tie-up with Accelerate Diagnostics is expected to strengthen the fight to combat the global threat of antimicrobial resistance, thereby boosting patient care.

Boston Scientific (BSX) Signs Obsidio-Acquisition Agreement

by Zacks Equity Research

Boston Scientific's (BSX) latest acquisition will add the FDA-approved GEM technology to its interventional oncology and embolization portfolio.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental performance and Cantel Medical buyout.

Abiomed's (ABMD) Impella Favored by Latest Study Result

by Zacks Equity Research

Abiomed's (ABMD) Impella-supported high-risk PCI leads to significant improvements in cardiovascular patient outcomes, per latest study.

Quest Diagnostics' (DGX) Base Volume Revives, New Ruling Aids

by Zacks Equity Research

With a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.

Here's Why You Should Retain Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.

West Pharmaceutical's (WST) Latest Investment to Boost Business

by Zacks Equity Research

West Pharmaceutical's (WST) minority investment is expected to aid in meeting patients' continuously evolving needs of ease of use and effective methods of medicine delivery.

Charles River (CRL) Business Hurt by Macro and FX Headwinds

by Zacks Equity Research

In Q2, the impact of foreign currency translation reduces Charles River's (CRL) reported revenue growth by 3.4%.

Here's Why You Should Buy Patterson Companies (PDCO) Stock

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of 63.08% and 8.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) Q4 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Cardinal Health's (CAH) fiscal fourth-quarter results benefit from a solid performance in the Pharmaceutical segment.

Catalent (CTLT) to Acquire New CDMO Facility for $475 Million

by Zacks Equity Research

Catalent (CTLT) agrees to buy Mayne Pharma's specialty CDMO division, Metrics Contract Services, for $475 million. The deal is expected to be completed by 2022-end.

CONMED (CNMD) Acquires Soft Tissue Implant Start-Up Biorez

by Zacks Equity Research

CONMED (CNMD) acquires privately-held Biorez, Inc. for $85 million. The deal is set to boost CONMED's sports medicine portfolio with the addition of Biorez's proprietary BioBrace Implant technology.

Shockwave Medical (SWAV) Beats on Q2 Earnings & Revenues

by Zacks Equity Research

Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and expansion in gross margin.

DENTSPLY SIRONA (XRAY) Up on Strong Q2 Preliminary Results

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) preliminary second-quarter 2022 results reflect the normalizing business, aided by product launches and pricing adjustments. Shares rise.

PDCO vs. CNMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PDCO vs. CNMD: Which Stock Is the Better Value Option?

McKesson (MCK) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

McKesson (MCK) delivered earnings and revenue surprises of 9.79% and 5.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Despite Fast-paced Momentum, Patterson Cos. (PDCO) Is Still a Bargain Stock

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Patterson Cos. (PDCO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Why Patterson Cos. (PDCO) Could Beat Earnings Estimates Again

by Zacks Equity Research

Patterson Cos. (PDCO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.